The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer.

ABSTRACT:

Purpose

Low expression of HER2 (HER2-low expression) in breast cancer (BC) has unique biological characteristics. However, whether HER2-low expression has an impact on neoadjuvant chemotherapy (NACT) in HER2-negative breast cancer remains unclear.

Methods

This study reviewed the clinicopathological data of patients with BC treated with NACT at a single hospital from January 2018 to July 2022. Baseline patient characteristics, efficacy of NACT, and survival data were compared between the HER2-0 and HER2-low groups. The impact of NACT on HER2 status also was investigated. Subgroup analyses based on hormone receptor (HR) status were performed to explore the impact of HR signaling on HER2 status during chemotherapy.

Results

The progesterone receptor-positive rate in the H

SUBMITTER: Wang W 

PROVIDER: S-EPMC10202994 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature